Egg-Scanning AI May Let Hatcheries Sort Life, Death and Sex Before Chicks Emerge
University of Illinois researchers have demonstrated that hyperspectral imaging combined with machine‑learning can predict chicken‑egg outcomes before chicks hatch. Their model identified dead embryos with 97% accuracy by day 4 and classified sex at day 0 with 75% accuracy. The approach is non‑destructive, requiring only a scan rather than invasive testing. The team is also developing a robotic arm to automatically sort eggs based on the AI’s predictions, aiming to curb the industry’s routine male‑chick culling.
Ultralow-Temperature Cryoablation Shows Promise for VT
The FULCRUM‑VT IDE trial evaluated Adagio Medical’s vCLAS ultralow‑temperature cryoablation system in 209 patients with monomorphic ventricular tachycardia. At six months, 59% of participants remained free of recurrent VT, ICD interventions, and antiarrhythmic escalation, while acute success reached 98% non‑inducibility....
ScPlantReg Decodes Plant Chromatin Accessibility, Regulation
scPlantReg, a new deep‑learning framework, translates plant ATAC‑seq and RNA‑seq data into high‑resolution maps of chromatin accessibility and gene regulation. The platform was benchmarked on Arabidopsis, maize and wheat, achieving over 80% predictive accuracy for tissue‑specific enhancers. By linking accessible...
FDA Warns Public About Vascular Device After 3 Deaths
The FDA issued an early‑alert notice on Terumo Aortic’s Relay Pro Thoracic Stent Graft system after three deaths were linked to a failure of the device to unclasp from its delivery system. The warning applies to the non‑bare stent configuration sized...
New Blood-Based Method Identifies Testicular Cancer Missed by Standard Tests
Mayo Clinic scientists unveiled a blood‑based assay, GCT‑iSIGN, that detects germ cell tumors with 93% sensitivity and 99% specificity, even when conventional tumor markers are negative. In a cohort of 427 samples, the test caught 23 of 24 cases missed...
Multiple Myeloma Sequencing Evolves With CAR T, MRD Insights: Sylvester Homsy, MD
At an Institute for Value‑Based Medicine event in Charlotte, Sylvester Homsy, MD highlighted how CAR‑T cell therapy and bispecific antibodies are reshaping multiple myeloma treatment sequencing. The emergence of B‑cell maturation antigen‑targeted agents is prompting clinicians to consider these high‑efficacy...
US Pricing Reform Reshapes Drug Launch Strategies: Dee Chaudhary
U.S. drug‑pricing reforms, especially the Most Favored Nation (MFN) rule, are forcing manufacturers to align American prices with the lowest prices offered abroad. As a result, firms are pulling back from launches in France, Germany and the Nordic region to...
Scientists Uncover a Hidden Mechanism Cancer Cells Use to Rewrite Genetic Messages, Revealing a Promising New Target for Treatment
A team of molecular biologists has uncovered a previously unknown RNA‑binding protein that rewrites messenger‑RNA messages in cancer cells, effectively reprogramming gene expression. The discovery explains how tumors can rapidly adapt to hostile environments and develop resistance to standard chemotherapy....
Method Identifies Cellular Makeup of Microenvironments Favoring Tumor Metastasis
Researchers at Baylor College of Medicine introduced Sortase A‑Based Microenvironment Niche Tagging (SAMENT), a technique that chemically labels normal cells directly contacted by metastatic cancer cells. Using SAMENT across bone, lung, liver and brain models, they identified a common niche...
WHO Designates Network of Regional Biomanufacturing Training Centers
The World Health Organization has officially designated a network of regional biomanufacturing training centers spanning all six WHO regions, marking a major step in building a skilled global workforce for vaccines, biotherapeutics and other biologics. The centers—located in Senegal, South...
New AI Models Quickly Find Compounds that Target Lyme Bacteria
Tufts University researchers have leveraged AI and machine‑learning to rapidly pinpoint narrow‑spectrum antibiotics that kill the Lyme disease bacterium Borrelia burgdorferi. Screening 60,000 existing compounds yielded several hundred hits, and generative models now explore an estimated 10^60 drug‑like molecules to...
Advanced Gene Editing ‘Promising’ for Sickle Cell Disease
Two recent New England Journal of Medicine studies demonstrate that CRISPR‑Cas12a (reni‑cel) and base‑editing (risto‑cel) autologous stem‑cell therapies can dramatically raise fetal hemoglobin and normalize total hemoglobin in sickle cell patients. The RUBY trial reported a rise from 2.5% to...
FDA Debuts Plan to Collect Real-Time Clinical Trial Data
The U.S. Food and Drug Administration announced a pilot program that will collect clinical‑trial data in real time, allowing scientific reviewers to see information as it is generated. The initiative, launched on Tuesday, includes participation from major drugmakers AstraZeneca and...
GLP-1 Receptor Agonist Add-On at Immune Checkpoint Inhibitor Initiation and Fewer Wasting-Related Diagnoses and Acute-Care Episodes in People with Cancer...
A target‑trial emulation of US TriNetX data examined cancer patients with obesity who started immune checkpoint inhibitors (ICIs) and received a GLP‑1 receptor agonist (GLP‑1 RA) at initiation. After 1:1 propensity matching, 988 patients per arm were followed for up to...
Stick-On Gel Delivers Drugs Directly to Plants to Clear Infections Quickly
UC San Diego engineers have created a stick‑on adhesive gel that can be loaded with drugs or nanoparticles and applied directly to plant surfaces, delivering cargo systemically and clearing bacterial infections within 48 hours. The gel combines polyacrylamide for flexibility...
Pfizer Delays Patent Cliff for Blockbuster Vyndamax
Pfizer announced a two‑year extension of market exclusivity for Vyndamax (tafamidis), pushing the expected generic launch to 2026. The extension stems from a new formulation patent and a pediatric study that grant additional protection. Vyndamax, approved for transthyretin amyloid cardiomyopathy,...
Dual-Agonist Survodutide Shows Significant Weight Loss in Phase III Obesity Trial
Boehringer Ingelheim reported that its dual glucagon/GLP‑1 agonist survodutide produced up to 16.6% average weight loss after 76 weeks in the Phase III SYNCHRONIZE‑1 trial. The study also showed that 85.1% of treated participants achieved at least a 5% reduction, with...
Insecticidal Metabolites From Serratia Marcescens Associated with the Fall Armyworm (Spodoptera Frugiperda): Metabolomic Profiling and Molecular Docking Insights
Researchers isolated Serratia marcescens strain INS420 from fall armyworm and identified a range of secondary metabolites using LC‑MS and GC‑MS. Laboratory and field tests showed these compounds have strong insecticidal activity against Spodoptera frugiperda. Molecular docking indicated that squalene and...
BIOTECanada Responds to Health Canada’s Gazette on a Draft Order Providing for Reliance on International Regulatory Authorities
Health Canada’s Gazette released a draft Order that would allow Canadian regulators to rely on approvals from trusted foreign agencies, a key component of the Red Tape Review initiative. BIOTECanada praised the proposal, calling it a meaningful step toward faster...
FDA Grants RMAT Status to Orca-Q in High-Risk Hematologic Malignancies
The U.S. Food and Drug Administration has awarded Regenerative Medicine Advanced Therapy (RMAT) designation to Orca‑Q, an investigational allogeneic T‑cell immunotherapy targeting high‑risk hematologic malignancies. The designation follows early phase 1 data that hint at improved overall survival, lower graft‑versus‑host disease...
Scientists May Have Finally Created a Male Birth Control Pill—So Far, It Shows Very Few Side Effects
YourChoice Therapeutics reported that its experimental male contraceptive pill YCT‑529 was well‑tolerated in a Phase 1 trial of 16 healthy, vasectomized men. The non‑hormonal compound halted sperm production without altering testosterone, heart rate, mood, or sexual desire. Pre‑clinical work in mice...
EU Introduces Regulations for Crops Bred Through New Genomic Techniques
The European Commission has approved a new regulatory framework for crops bred with new genomic techniques (NGTs), pending European Parliament ratification and slated to take effect in mid‑2028. The rules create two categories: Category 1 plants, which are treated like conventional...
$739 Million Acquisition of XOMA Strengthens Ligand’s Biopharma Portfolio
Ligand Pharmaceuticals announced a $739 million acquisition of XOMA Royalty, expanding its royalty‑financing portfolio to over 200 assets. The deal adds more than 120 new royalty streams, including seven marketed drugs such as Vabysmo and Ojemda, and deepens exposure to oncology,...
Handle with Care: Mobile Microgrippers Pick up Cells in a Pinch
Researchers at Purdue University unveiled a force‑sensing mobile microgripper (MMG) that uses magnetic fields to gently pick up and arrange fragile cell spheroids for tissue engineering. The device provides real‑time grip feedback, preventing damage during manipulation. In‑vitro tests showed successful...
Rocket's PRV Goes for $180M; Oruka Targets $500M Offering
New Jersey‑based Rocket Pharmaceuticals sold its pediatric‑disease priority‑review voucher for $180 million, setting a near‑record price for such assets. The cash infusion strengthens Rocket’s balance sheet as it advances late‑stage gene‑therapy candidates. Meanwhile, biotech firm Oruka Therapeutics announced plans to raise...
BeOne Medicines Licenses Trispecific Antibody Targeting PD-1, CTLA-4 and VEGF
BeOne Medicines, the rebranded former BeiGene, announced a licensing and option agreement to acquire a trispecific antibody that simultaneously targets PD‑1, CTLA‑4, and VEGF. The experimental biologic originates from a Chinese biotech and is positioned for development in solid‑tumor indications....
Boehringer, Zealand’s Obesity Drug ‘More Akin’ to Novo’s Wegovy in Phase 3
Boehringer Ingelheim and Zealand Pharma reported that their glucagon/GLP‑1 dual agonist survodutide achieved a 13.4% (39.2 lb) average weight loss after 76 weeks in the Phase 3 SYNCHRONIZE‑1 trial, meeting primary endpoints and reducing waist circumference. Analysts compared the outcome to Novo...
AACR 2026: Combo Therapies by Moderna, Marengo Show Promise in Skin, Breast Cancer
Combination regimens dominated AACR 2026, with biotech firms showcasing new cocktail data across multiple tumor types. Marengo Therapeutics reported that its dual‑T‑cell agonist invikafusp alfa combined with Gilead’s ADC Trodelvy produced complete or partial responses in 40% of heavily pretreated...
Crafting Flavor in Hydroponically Grown Lettuce with CRISPR
Researchers used CRISPR/Cas9 to knock out the DFR gene in red‑leaf lettuce, producing a green‑pigmented line without compromising growth. The edited plants lost anthocyanin coloration, while some lines showed a rise in total flavonoids. Metabolite profiling confirmed a sharp drop...
Executing Biologics Technology Transfer Through Integrated Operating Models
The article advocates replacing the traditional sequential biologics tech‑transfer model with an integrated operating model that colocates development, manufacturing, MSAT and quality teams. By running small‑scale experiments and large‑scale runs concurrently, organizations can observe scale‑dependent effects in real time and...
Milestone for Crispr: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial
Intellia Therapeutics announced that its CRISPR‑based, one‑time gene‑editing therapy Lonzo‑z cleared a Phase 3 trial for hereditary angioedema, cutting swelling attacks by 87%. The double‑blind, placebo‑controlled study treated 52 of 80 patients and left 62% attack‑free without ongoing medication. Results represent...
STAT+: Boehringer’s Obesity Drug Shows 16.6% Weight Loss; More Data Needed
Boehringer Ingelheim reported that its experimental obesity drug produced an average 16.6% weight loss in a mid‑stage trial, signaling strong efficacy against a disease affecting over 100 million Americans. The study involved roughly 300 participants over 68 weeks and showed improvements...
Probiotic Candidate Shows Potential to Suppress UTIs
Researchers reported that the probiotic strain Limosilactobacillus reuteri 3613‑1, which produces the antimicrobial compound reuterin, can inhibit key urinary and vaginal pathogens. In a randomized, double‑blind, placebo‑controlled trial of 130 healthy women taking the probiotic daily for 24 weeks, the...
Erasca Plummets Despite 'Phenomenal' Results In Pancreatic Cancer
Erasca (ERAS) shares tumbled more than 45% to $10.50 after a patient in its pancreatic cancer trial died from pneumonia, a known side effect of the RAS‑blocking drug class. The death occurred when the patient withdrew from supportive care, despite...
California Startup Fermeate Closes $2M Seed Round for Light-Based Fermentation Control Technology
California startup Fermeate closed a $2 million seed round led by Newfund Capital, with participation from SOSV and Ajinomoto Group Ventures. The company’s optogenetics platform embeds light‑sensitive proteins in microbes, allowing real‑time gene activation or repression via an external light‑delivery device...
Updated: AbbVie Flirts with Popular Pan-RAS Field in up to $1.45B Option to Acquire Kestrel
AbbVie has signed a deal giving it an option to acquire Kestrel Therapeutics for up to $1.45 billion, targeting Kestrel’s pan‑RAS inhibitor platform. The agreement includes an upfront payment and milestone‑based earn‑outs tied to regulatory and commercial milestones. Kestrel’s lead candidate,...
FDA Claims Trial 'Manipulation' Tainted Approval of ChemoCentryx Drug
The FDA has accused ChemoCentryx of manipulating key efficacy data in the pivotal Phase III trial that secured approval for its rheumatoid‑arthritis drug Tavneos. The agency says the new information renders the trial "tainted" and is moving to pull the treatment...
The US FDA Grants Priority Review and Breakthrough Therapy Designation to GSK’s Bepirovirsen for Chronic Hepatitis B
The U.S. FDA has accepted GSK’s new drug application for bepirovirsen, granting both priority review and breakthrough therapy designation for chronic hepatitis B. The decision is based on Phase III B‑Well 1 and B‑Well 2 trials across 29 countries, which showed higher functional‑cure...
U.S. Medical Centers Need a New Model for Drug Discovery and Development
For more than half a century U.S. academic medical centers (AMCs) have supplied the majority of FDA‑approved drug patents, but China’s rapid R&D expansion threatens that dominance. Chinese biotech now leads in novel medicine approvals and offers clinical trials that...
As Biosimilars Gain US Traction, Patent Thickets Are Under More Scrutiny
Sun Pharma announced a $12 billion acquisition of Organon to accelerate its entry into the global biosimilar market. The FDA has now approved roughly 90 biosimilars, which account for about 23 % of the U.S. biologics market, reflecting growing competition. Patent thickets—large...
Precision Radiation Therapy Could Offer New Hope For Hard-To-Treat Cancers
Radionuclide therapy, a precision cancer treatment delivering radioactive atoms directly to tumors, is gaining regulatory approvals and market traction. The class, anchored by early successes like Xofigo and the FDA‑approved Pluvicto, is projected to reach a $10.7 billion market by 2030....
China Now Holds 75% of Gene-Edited Seed Patents as Europe Moves to Loosen NGT Rules
China now commands roughly three‑quarters of all gene‑edited seed patents, with 16,177 filings in 2024—five times the EU total. The European Union is moving to loosen its New Genomic Techniques (NGT) rules, introducing a flexible NGT 1 category that avoids the...
GSK Eyes October FDA Verdict on Chronic Hep B Drug
GlaxoSmithKline’s antisense drug bepirovirsen entered an accelerated FDA review, with a decision expected by October 26. The phase‑2 B‑WELL 1 and B‑WELL 2 trials showed a statistically higher functional cure rate versus placebo when added to standard hepatitis B therapy. If approved, bepirovirsen would...
Building the Future of Biotechnology — UK Biotech Day 2026
UK Biotech Day 2026 will take place on May 27‑28 at the Radisson Hotel near Heathrow, bringing together industry leaders, researchers, government officials, and investors. The two‑day event highlights the UK’s rapid biotech growth, showcasing therapeutic innovation, manufacturing advances, health‑tech...
Novartis’ Sales Dip as Generics Pressure Intensifies, Radioequivalents Loom
Novartias first‑quarter net sales slipped 5% to $13.11 billion, primarily due to U.S. generic erosion of its heart‑failure drug Entresto. While earnings per share fell 11% to $1.65, growth was buoyed by double‑digit gains in Kisqali, Kesimpta and the radiopharma Pluvicto....
Revolution Levels Legal Threat on Erasca as Pancreatic Cancer Rivalry Heats Up
Revolution Medicines, after its Phase 3 pancreatic cancer drug daroxinrasib showed a median overall survival of 13.2 months and lifted its share price, sent a cease‑and‑desist letter to rival Erasca demanding the U.S. halt of ERAS‑0015, alleging patent infringement and misleading...
How Wireless Tags Can Help Monitor Your Breathing
Researchers from Chalmers University of Technology, Sahlgrenska University Hospital and the University of Gothenburg have demonstrated a contactless method for monitoring breathing using plaster‑like RFID tags. In a proof‑of‑concept test on a mannequin, the tags captured subtle chest‑wall movements and...
We May Finally Have a Cure for Many Different Autoimmune Conditions
A novel cancer immunotherapy is being repurposed to eliminate rogue T‑cells that drive autoimmune diseases. Early trials show it can eradicate the pathogenic cells rather than merely suppressing symptoms, delivering faster and more durable remission. Dozens of global studies are...
Symptom-Based Approach Treats Opioid Withdrawal in Newborns with Minimal Drug Exposure
An NIH‑funded OPTimize NOW trial compared symptom‑based, as‑needed opioid dosing with traditional scheduled tapering for newborns with moderate to severe neonatal opioid withdrawal syndrome (NOWS). Among 383 infants cared for under the family‑centered Eat‑Sleep‑Console model, the symptom‑based group was ready for...
Oruka Reports Positive Data From Phase IIa Trial for Plaque Psoriasis
Oruka Therapeutics announced interim results from its EVERLAST‑A Phase IIa trial of ORKA‑001, a half‑life‑extended IL‑23p19 monoclonal antibody, in moderate‑to‑severe plaque psoriasis. Of the 63 patients receiving the 600 mg dose, 63.5% achieved PASI 100 by week 16, meeting the primary endpoint, with 83%...